Market closed

Tonix Pharmaceuticals/$TNXP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Ticker

$TNXP
Trading on

Industry

Biotechnology

Employees

81

TNXP Metrics

BasicAdvanced
$113M
-
-$176.60
2.24
-
$113M
2.24
$672.00
$6.76
1.9M
6.5
5.822
3.601
5.818
-30.62%
-106.12%
1.276
0.55
0.55
-0.211
29.94%

What the Analysts think about TNXP

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Tonix Pharmaceuticals stock.

TNXP Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TNXP Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TNXP

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Tonix Pharmaceuticals stock?

Tonix Pharmaceuticals (TNXP) has a market cap of $113M as of April 05, 2025.

What is the P/E ratio for Tonix Pharmaceuticals stock?

The price to earnings (P/E) ratio for Tonix Pharmaceuticals (TNXP) stock is 0 as of April 05, 2025.

Does Tonix Pharmaceuticals stock pay dividends?

No, Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders as of April 05, 2025.

When is the next Tonix Pharmaceuticals dividend payment date?

Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders.

What is the beta indicator for Tonix Pharmaceuticals?

Tonix Pharmaceuticals (TNXP) has a beta rating of 2.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.